Test Catalog

Test ID: F5NGS    
F5 Gene, Next-Generation Sequencing, Varies

Useful For Suggests clinical disorders or settings where the test may be helpful

Genetic confirmation of factor V deficiency with the identification of an alteration in the F5 gene known or suspected to cause the condition


Carrier testing for close family members of an individual with a factor V deficiency diagnosis


This test is not intended to evaluate for the factor V Leiden mutation.


This test is not intended for prenatal diagnosis.

Genetics Test Information Provides information that may help with selection of the correct genetic test or proper submission of the test request

This test detects pathogenic alterations in the F5 gene to delineate the underlying molecular defect in a patient with a laboratory diagnosis of coagulation factor V deficiency. This test may also detect rare alterations in F5 that cause activated protein C (APC) resistance, resulting in thrombophilia.


The gene target for this test is:

Gene name (transcript): F5 (GRCh37 [hg19] NM_000130)

Chromosomal location: 1q23-24

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

If the patient appears to have a bleeding disorder, the clinical workup for factor V deficiency (F5D) begins with special coagulation testing for factor V activity. See FACTV / Coagulation Factor V Activity Assay, Plasma.


Genetic testing for F5D is indicated if:

-Factor V activity is reduced and acquired causes of FV deficiency have been excluded

-The FVIII activity is normal (low factor V levels with concurrently low factor VIII levels suggest combined deficiency of factor V and FVIII [F5F8D], a condition with a genetic etiology different from that of F5D)


If the patient appears to have thrombophilia, the results of an activated protein C (APC) resistance assay indicate presence of resistance to APC, and factor V Leiden genotype does not correlate with the severity of thrombophilia or clinical presentation, full-gene sequencing of F5 may be warranted. If testing for factor V Leiden is desired instead of full-gene sequencing, please order "Factor V Leiden (R506Q) Mutation, Blood" (Mayo test ID F5DNA).

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Factor V is a critical cofactor of Xa in the conversion of prothrombin to thrombin. Factor V protein has both procoagulant and anticoagulant properties, and molecular defects in it may result in either bleeding or clotting.


Factor V deficiency (F5D, also known as parahemophilia) causes mild to severe bleeding problems, including nosebleeds, bruising, soft tissue and joint bleeds, menorrhagia, umbilical stump bleeding and post-operative bleeding. Intracranial bleeding has been reported in neonates, but bleeding episodes in the central nervous system and in the GI tract, in general, are reported to occur only rarely.(2,3) F5D is a rare with a prevalence of 1 per 1 million in the general population. The F5 gene encodes Factor V. Alterations in the F5 gene that reduce the amount of plasma factor V or disrupt its functional procoagulant activity cause F5D. Unlike some other factor deficiencies, there is no strict correlation between FV levels and disease state severity, as some patients with severe deficiency do not have severe bleeding despite low FV levels. However, it has been estimated that the minimum level of factor V needed to prevent symptoms is at least 10% of normal.(4) Hereditary factor V deficiency is considered to be an autosomal recessive disorder. Individuals homozygous or compound heterozygous for pathogenic F5D alterations usually have factor V plasma activity levels lower than 10%.(1) Heterozygous individuals typically have around 50% plasma factor V levels and are usually asymptomatic.(1) Causes of acquired (non-genetic) F5D that should be excluded prior to genetic testing include the development of inhibitors directed against factor V after exposure to bovine thrombin or in association with risk factors like surgical procedures, antibiotic administration, blood transfusions, cancers, and autoimmune disorders.(1) In addition, liver disease or consumptive coagulopathy may result in low factor V levels.


Defects in factor V may be associated with an increased risk of thrombosis. Activated protein C (APC) reduces the thrombotic activity of factor V by proteolytically cleaving certain sites in the protein. Point alterations at these cleavage sites make factor V resistant to this inactivation (ie, cause APC resistance), abnormally prolonging its procoagulant properties and increasing the risk for thrombosis. The vast majority of individuals with familial APC resistance have a specific point alteration in the F5 gene called factor V Leiden (historically known as "R506Q" or "1691G>A"). Five percent of factor V Leiden heterozygotes develop thromboembolism by 65 years of age. Other far less common factor V alterations also cause APC resistance and have different thrombotic risks. The coinheritance of both a pathogenic APC-resistant F5 gene alteration and a F5 gene alteration that causes F5D (ie, "pseudohomozygosity") also results in an increased risk for thrombosis. The hereditary thrombophilia that results from F5 alterations causing APC-resistance is inherited in an autosomal dominant manner that is incompletely penetrant (ie, the presence of a pathogenic variant increases the risk for but does not guarantee manifestation of disease).


These risks are further influenced by additional risk factors, such as oral contraceptive use, hyperhomocysteinemia, pregnancy, blood type, and the inheritance of other molecular defects in genes associated with heritable thrombophilia (eg, deficiencies in protein S and protein C). Still other factors can impair activity of activated protein C such as increased factor VIII, increased estrogen levels, antiphospholipid antibodies, cancer, elevated BMI, and smoking. The prevalence of alterations in F5 that cause APC resistance other than factor V Leiden is unknown. Full gene sequencing of F5 may be warranted if APC resistance assay (see APCRV / Activated Protein C Resistance V [APCRV], Plasma) suggests abnormal resistance to activated protein C and factor V Leiden genotype does not correlate with the severity of thrombophilia or clinical presentation. During testing for APC resistance, care should be taken to avoid, when possible, certain preanalytical conditions of the patient and blood specimen that may interfere with results. Examples include the presence of lupus-like anticoagulants and specific coagulation factor inhibitors, excessive exposure to estrogen, and markedly elevated levels of factor VIII.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretive report will be provided

Interpretation Provides information to assist in interpretation of the test results

An interpretive report will be provided.


Evaluation and categorization of variants is performed using the most recent published American College of Medical Genetics and Genomics (ACMG) recommendations as a guideline. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.


Consultations with the Mayo Clinic Special Coagulation Clinic, Molecular Hematopathology Laboratory or Thrombophilia Center are available for DNA diagnosis cases. This may be especially helpful in complex cases or in situations where the diagnosis is atypical or uncertain.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances


Some individuals may have a mutation that is not identified by the methods performed. The absence of a mutation, therefore, does not eliminate the possibility of factor V deficiency (F5D) or a related disorder such as combined factor V and VIII deficiency (F5F8D), which occurs due to alterations in LMAN1 (ERGIC-53) or MCFD2. This assay does not distinguish between germline and somatic alterations, particularly with variant allele frequencies (VAF) significantly lower than 50%. Test results should be interpreted in context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.


Technical Limitations:

Next-generation sequencing (NGS) may not detect all types of genetic variants. Additionally, rare polymorphisms may be present that could lead to false negative or positive results. Therefore test results should be interpreted in the context of activity and antigen measurements, clinical findings, family history, and other laboratory data. If results do not match clinical findings, consider alternative methods for analyzing these genes, such as Sanger sequencing or large deletion/duplication analysis. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.


If multiple alterations are identified, NGS is not able to distinguish between alterations that are found in the same allele ("in cis") and alterations found on different alleles ("in trans"). This limitation may complicate diagnosis or classification and has implications for inheritance and genetic counseling. To resolve these cases, molecular results must be correlated with clinical history, activity and antigen measurements, and family studies.


Unless reported or predicted to cause disease, alterations found deep in the intron or alterations that do not result in an amino acid substitution are not reported. These and common polymorphisms identified for this patient are available upon request.


Reclassification of Variants Policy:

At this time, it is not standard practice for the laboratory to systematically review likely pathogenic variants or variants of uncertain significance that are detected and reported. The laboratory encourages health care providers to contact the laboratory at any time to learn how the status of a particular variant may have changed over time.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Lippi G, Favaloro EJ, Montagnana M, et al: Inherited and acquired factor V deficiency. Blood Coagul Fibrinolysis 2011;22(3):160-166

2. Asselta R, Peyvandi F: Factor V deficiency. Semin Thromb Hemost 2009;35(4):382-389

3. Mumford AD, Ackroyd S, Alikhan R, et al: Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014;167(3):304-326

4. Palla R, Peyvandi F, Shapiro AD: Rare bleeding disorders: diagnosis and treatment. Blood 2015;125(13):2052-2061

5. Rosendaal FR, Koster T, Vandenbroucke JP, et al: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85(6):1504-1508

6. Van Cott EM, Khor B, Zehnder JL: Factor V Leiden. Am J Hematol 2016;91(1):46-49

7. Dahlback B: Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders. Int J Lab Hem 2016;38(Suppl 1):4-11

Special Instructions Library of PDFs including pertinent information and forms related to the test